5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.12▲ | 2.12▲ | 2.13▼ | 2.24▼ | 2.40▼ |
MA10 | 2.14▼ | 2.18▼ | 2.20▼ | 2.48▼ | 2.16▼ |
MA20 | 2.21▼ | 2.22▼ | 2.23▼ | 2.41▼ | 1.85▲ |
MA50 | 2.25▼ | 2.32▼ | 2.45▼ | 2.11▼ | 3.13▼ |
MA100 | 2.41▼ | 2.48▼ | 2.43▼ | 1.85▲ | 10.20▼ |
MA200 | 2.48▼ | 2.41▼ | 2.30▼ | 2.52▼ | 27.85▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.010▼ | -0.006▼ | -0.004▼ | -0.072▼ | 0.222▲ |
RSI | 35.970▼ | 34.557▼ | 32.980▼ | 42.422▼ | 45.695▼ |
STOCH | 11.202▼ | 8.215▼ | 12.064▼ | 13.641▼ | 68.735 |
WILL %R | -88.372▼ | -88.372▼ | -88.372▼ | -98.000▼ | -55.515 |
CCI | -62.500 | -83.517 | -125.304▼ | -109.719▼ | 42.276 |
Sunday, July 06, 2025 05:01 PM
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today ...
|
Monday, June 30, 2025 12:00 AM
ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central ...
|
Monday, February 24, 2025 04:00 PM
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
11/07/25 | 2.20 | 2.26 | 2.08 | 2.10 | 170,923 |
10/07/25 | 2.26 | 2.3299 | 2.21 | 2.24 | 94,781 |
09/07/25 | 2.27 | 2.3195 | 2.21 | 2.275 | 82,380 |
08/07/25 | 2.31 | 2.47 | 2.20 | 2.32 | 120,176 |
07/07/25 | 2.45 | 2.47 | 2.2202 | 2.27 | 155,332 |
03/07/25 | 2.55 | 2.59 | 2.34 | 2.44 | 110,186 |
02/07/25 | 2.34 | 2.6969 | 2.1625 | 2.57 | 448,457 |
01/07/25 | 2.96 | 3.0289 | 2.76 | 2.86 | 459,211 |
30/06/25 | 2.84 | 3.0799 | 2.51 | 2.90 | 985,265 |
27/06/25 | 2.72 | 2.86 | 2.56 | 2.79 | 476,861 |
|
|
||||
|
|
||||
|
|